Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leuke
Author: ["Jeffrey J. Molldrem","Peter P. Lee","Changqing Wang","Kyrie Felio","Hagop M. Kantarjian","Richard E. Champlin","Mark M. Davis"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Although the immune system has long been implicated in the control of cancer, evidence for specific and efficacious immune responses in human cancer has been lacking. In the case of chronic myelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-α2b (IFN-α2b) therapy can result in complete remission, but the mechanism for prolonged disease control is unknown and may involve immune anti-leukemic responses. We previously demonstrated that PR1, a peptide derived from proteinase 3, is a potential target for CML-specific T cells. Here we studied 38 CML patients treated with allogeneic BMT, IFN- α2b or chemotherapy to look for PR1-specific T cells using PR1/HLA-A*0201 tetrameric complexes. There was a strong correlation between the presence of PR1-specific T cells and clinical responses after IFN-α and allogeneic BMT. This provides for the first time direct evidence of a role for T-cell immunity in clearing malignant cells.
Cite this article
Molldrem, J., Lee, P., Wang, C. et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6, 1018–1023 (2000). https://doi.org/10.1038/79526
